Board Change • 18h
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Director Clare Fisher was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Apr 20
Molecular Partners Presents Three Posters At AACR 2026, with New Preclinical Data for First Switch-DARPin T Cell Engager MP0632 and DLL3 Radio-DARPin MP0712 Molecular Partners AG announced the presentation of new preclinical data across three posters at the American Association for Cancer Research Annual Meeting 2026. The first poster outlines preclinical data supporting proof-of-concept for MP0632, a logic-gated Switch-DARPin CD3 T cell engager with CD2 co-stimulation designed to selectively kill cells co-expressing mesothelin (MSLN) and epithelial cell adhesion molecule (EpCAM). MP0632 leads to regression of established tumors expressing both EpCAM and MSLN, with minimal impact on tumors expressing only one antigen, indicating a favorable therapeutic window. In addition, the Switch-DARPin candidate allowed for safe use of potent costimulation for efficient tumor cell killing with low cytokine release profile. The data support MP0632’s potential as clinical lead candidate for the treatment of ovarian cancer and other MSLN- and EpCAM-positive solid tumors. The second poster presents a computational workflow to identify and prioritize tumor-associated antigen pairs for improved tumor-selectivity and safety in support of designing novel Switch-DARPin candidates, such as MP0632. This scalable, data-driven platform provides a strong foundation for the discovery of next-generation multispecific immunotherapies. This workflow could also be leveraged for the identification of complementary tumor antigen pairs to address heterogeneous tumors, which could enable the design of next-generation multispecific Radio-DARPin candidates. The third poster outlines the molecular characteristics of MP0712, the Company’s first 212Pb-based Radio-DARPin candidate, with high affinity binding to DLL3 and optimized half-life extended properties. MP0712’s properties are hypothesized to facilitate sustained tumor uptake through repeated DLL3 internalization-replenishment despite low cell surface density of the target, thereby supporting the attractive biodistribution profile of MP0712 observed in preclinical studies as well as in first patient imaging data from a Named Patient Access Program in South Africa using MP0712 with 203Pb. MP0712, co-developed with strategic partner Orano Med, is evaluated in an ongoing Phase 1/2a trial in the US for the treatment of patients with small cell lung cancer and other DLL3-expressing neuroendocrine cancers. Details of the presentations at AACR 2026: Logic-gated Switch-DARPin T cell engager with CD2 co-stimulation for improved safety and efficacy in MSLN and EpCAM co-expressing ovarian cancer Session Category: Immunology Session Title: T Cell Engagers 1 Session Start: 4/20/2026 9:00 AM PT Session End: 4/20/2026 12:00 PM PT Location: Poster Section 10 Poster Board Number: 16 Poster Number: 1624 Logic-gated Switch-DARPin–based immune cell engagers guided by data-driven tumor-antigen profiling: A computational workflow for the development of cancer immunotherapies Session Category: Bioinformatics /Computational Biology /Systems Biology /Convergent Science Session Title: Application of Bioinformatics to Cancer Biology 3 Session Start: 4/20/2026 2:00 PM PT Session End: 4/20/2026 5:00 PM PT Location: Poster Section 1 Poster Board Number: 16 Poster Number: 2691 Molecular characteristics of MP0712, a clinical stage 212Pb-based Radio-DARPin candidate for targeted anti-DLL3 radiotherapy of small cell lung cancer Session Category: Experimental and Molecular Therapeutics Session Title: Targeted Radiopharmaceuticals and Combination Strategies in Cancer Therapy Session Start: 4/22/2026 9:00 AM PT Session End: 4/22/2026 12:00 PM PT Location: Poster Section 17 Poster Board Number: 16 Poster Number: 7197 The posters will be made available on Molecular Partners' website after the presentations. Announcement • Apr 15
Molecular Partners AG Announces Board and Committee Appointments Molecular Partners AG announced that Clare Fisher was elected by shareholders to its Board of Directors at the AGM held on April 14, 2026. Clare Fisher is currently the SVP for Global Business Development and M&A at BeOne Medicines, a global oncology company committed to discovering and developing innovative treatments for cancer patients worldwide. Clare has more than two decades of healthcare experience in leadership roles, including corporate and business development, mergers and acquisitions, and strategy. She joined BeOne from Kaleido, where she served as Chief Business Officer. Previously Clare worked at Shire plc (now Takeda), where she was Group Vice President, Global Head of Transactions and Business Development, and Interim Head of Corporate Development. She also held senior roles in business development at Cubist Pharmaceuticals, Blueprint Medicines, and Genzyme Corporation. Clare Fisher earned a B.S. in biochemistry from the University of Bath and an MBA from Henley Management College in the U.K. Agnete Fredriksen was elected to the Nomination and Compensation Committee, in place of Steven H. Holtzman. Announcement • Mar 30
Molecular Partners Ag Announces That Current Board Member Steven H. Holtzman Will Not Stand for Re-Election Molecular Partners AG announced that at the Annual General Meeting will be held on April 14, 2026 Current Board member Steven H. Holtzman will not stand for re-election following 12 years of service on the BoD of Molecular Partners. Announcement • Mar 24
Molecular Partners AG, Annual General Meeting, Apr 14, 2026 Molecular Partners AG, Annual General Meeting, Apr 14, 2026, at 09:00 W. Europe Standard Time. Location: at jed events, zurcherstrasse 39, 8952 schlieren, Switzerland Announcement • Mar 20
Molecular Partners AG Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability To Multiple Isotopes Molecular Partners AG announced it will hold an oral presentation outlining new preclinical data on Radio-DARPins at the 3rd Global Radiopharmaceuticals Development Summit, taking place in Shanghai, China on March 19–20, 2026. The presentation will outline the Radio-DARPins’ suitability to different isotopes with data on two Radio-DARPin candidates, each specific for a different tumor target. The results of studies in tumor-bearing mice show highly comparable biodistribution profiles for both Radio-DARPin candidates labeled with Lutetium-177 (177Lu) or with Lead-203 (203Pb), with similar uptake and washout rates. Imaging with 177Lu can be indicative of behavior with the therapeutic isotope Actinium-225 (225Ac), and similarly with 203Pb for 212Pb. Details of the presentation DARPins for targeted alpha therapy: from promising MP0712 first in-human data to opportunities for next Radio-DARPin candidates Presenter: Daniel Steiner, Ph.D., SVP of Technology and Research Time: 9:25 am CST, Friday, March 20 Location: Meeting Room B – IND Filing and Clinical Development Progress. MP0712, Molecular Partners’ DLL3-targeted 212Pb-based Radio-DARPin candidate co-developed with strategic partner Orano Med, is in an ongoing Phase 1/2a trial in the US (NCT07278479). Imaging data of MP0712 carrying the diagnostic isotope 203Pb under compassionate care are supportive of clinical development plans of MP0712 carrying the therapeutic isotope 212Pb for patients with small cell lung cancer (SCLC) and other DLL3-expressing neuroendocrine cancers. In February 2026, Molecular Partners entered into an agreement with Eckert & Ziegler, specialist in isotope-related components for nuclear medicine and radiation therapy, to enable the development and manufacturing of Radio-DARPin therapeutics. Eckert & Ziegler will support Molecular Partners with a comprehensive range of services covering development activities for Radio-DARPins with 225Ac as therapeutic payload and 177Lu as imaging payload. Molecular Partners’ Radio-DARPins are designed as ideal vectors for precise delivery of potent alpha-emitting isotopes to tumor lesions and have the potential to unlock a broad range of tumor targets for targeted radiopharmaceuticals. Building on the DARPins’ unique properties, Molecular Partners has developed a proprietary Radio-DARPin platform to address historic limitations of radioligand therapy, such as kidney accumulation and toxicity, and suboptimal tumor uptake. Molecular Partners’ Radio-DARPins addresses these limitations through half-life extension technologies and surface engineering approaches, while preserving the advantages of the small protein format. DARPin (Designed Ankyrin Repeat Protein) therapeutics are a novel class of protein drugs based on natural binding proteins, which have been clinically validated across several therapeutic areas and developed through to the registrational stage. The key properties of DARPins – intrinsic high affinity and specificity, small size, flexible architecture, and high stability – offer unmatched advantages to drug design, such as multispecificity, broad target range, and tunable half-life. The Company’s Radio-DARPins enable highly effective and specific delivery of potent radioactive payloads to tumor lesions while sparing healthy tissues. Molecular Partners’ Switch-DARPins allow conditional, tumor-localized immune activation, which enables increased safety and potency for next-generation immune cell engagers. Powered by twenty years of DARPin leadership in the clinic, Molecular Partners has built an innovative, rapid and cost-effective DARPin drug design engine, including proprietary DARPin libraries and platforms, for candidates produced with optimized properties and tailored to therapeutic needs. 
